Our Strategy

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

Typical Investments

Investment size$15-$30m in total per company
OwnershipMajority or minority
GeographyPrimarily US and Europe
Holding period3-8 years
SectorsBiotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation

BROAD STRATEGIC APPROACH

Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Discover the Strategies

Covering programmes and companies at many different stages of development, our diverse strategies provide us with unusually broad insights into the key factors for success in biotechnology.

"I was impressed by Abingworth’s thoughtful, candid and rigorous diligence process, and their interest in building a relationship with management before they became investors. That approach created mutual understanding and trust, and laid the foundation for a highly productive partnership."

Timothy Noyes, President and CEO of Proteon Therapeutics

"I have found Abingworth to be extremely supportive in positioning Paratek for success. In addition to providing finance and executive leadership, their deep knowledge of the sector and extensive network have proven to be invaluable in creating value for the company today and in the future."

Evan Loh, President of Paratek Pharmaceuticals

"Abingworth is an excellent investor for GammaDelta Therapeutics. Using strong scientific expertise and astute business sense they drove the seed investment with King’s College and the Crick institute and then our highly productive collaboration with Takeda. High quality science and ethical behaviour form the foundation of day-by-day activities at Abingworth and it is extremely reassuring to have such partners."

Paolo Paoletti, CEO of GammaDelta Therapeutics

"Abingworth was the first institutional investor to reach out directly to VenatoRx, even before we were looking to fund-raise. They have excellent knowledge of the infectious disease domain space and had clearly done their homework. We enjoy a strong collaborative relationship that adds significant value to the company."

Christopher Burns, CEO of VenatoRx

"Abingworth are a very hands-on investor who bring their extensive experience in the life sciences sector to the board table. They have been a great support and used their connections to source exceptional individuals to join our growing company."

Allison Jeynes-Ellis, CEO of Avillion